APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmaceutical Safety Assessment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmaceutical Safety Assessment Market Outlook and Growth Opportunities 2026

3 May 2026194 pages

Choose your research edition.

Industry ResearchPharmaceutical Safety Assessment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmaceutical Safety Assessment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pharmaceutical Safety Assessment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmaceutical Safety Assessment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmaceutical Safety Assessment Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Pharmaceutical Safety Assessment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pharmaceutical Safety Assessment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharmaceutical Safety Assessment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharmaceutical Safety Assessment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pharmaceutical Safety Assessment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pharmaceutical Safety Assessment market include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage and Medicilon, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pharmaceutical Safety Assessment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmaceutical Safety Assessment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmaceutical Safety Assessment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmaceutical Safety Assessment market.

Pharmaceutical Safety Assessment Segment by Company

Eurofins

LabCorp

Fujifilm Wako

Charles River

SGS

Intertek Group

CTI

Frontage

Medicilon

Wuxi Biologics

Pharmaron

Pharmaceutical Safety Assessment Segment by Type

Biological Drugs

Chemical Drugs

Pharmaceutical Safety Assessment Segment by Application

Clinical

Non-clinical

Pharmaceutical Safety Assessment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmaceutical Safety Assessment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharmaceutical Safety Assessment key companies, revenue, market share, and recent developments.

3. To split the Pharmaceutical Safety Assessment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharmaceutical Safety Assessment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmaceutical Safety Assessment significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmaceutical Safety Assessment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Safety Assessment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Safety Assessment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Safety Assessment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmaceutical Safety Assessment industry.

Chapter 3: Detailed analysis of Pharmaceutical Safety Assessment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharmaceutical Safety Assessment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharmaceutical Safety Assessment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmaceutical Safety Assessment Industry Trends Table 2. Pharmaceutical Safety Assessment Industry Drivers Table 3. Pharmaceutical Safety Assessment Industry Opportunities and Challenges Table 4. Pharmaceutical Safety Assessment Industry Restraints Table 5. Global Pharmaceutical Safety Assessment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmaceutical Safety Assessment Revenue Share by Company (2021-2026) Table 7. Global Pharmaceutical Safety Assessment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharmaceutical Safety Assessment Key Company Manufacturing Base & Headquarters Table 9. Global Pharmaceutical Safety Assessment Company, Product Type & Application Table 10. Global Pharmaceutical Safety Assessment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharmaceutical Safety Assessment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Biological Drugs Table 15. Significant Companies of Chemical Drugs Table 16. Global Pharmaceutical Safety Assessment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Pharmaceutical Safety Assessment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Pharmaceutical Safety Assessment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Pharmaceutical Safety Assessment Sales Value Share by Type (2021-2026) Table 20. Global Pharmaceutical Safety Assessment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Clinical Table 22. Significant Companies of Non-clinical Table 23. Global Pharmaceutical Safety Assessment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Pharmaceutical Safety Assessment Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Pharmaceutical Safety Assessment Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Pharmaceutical Safety Assessment Sales Value Share by Application (2021-2026) Table 27. Global Pharmaceutical Safety Assessment Sales Value Share by Application (2027-2032) Table 28. Global Pharmaceutical Safety Assessment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pharmaceutical Safety Assessment Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Pharmaceutical Safety Assessment Sales Value Share by Region (2021-2026) Table 31. Global Pharmaceutical Safety Assessment Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Pharmaceutical Safety Assessment Sales Value Share by Region (2027-2032) Table 33. Global Pharmaceutical Safety Assessment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pharmaceutical Safety Assessment Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Pharmaceutical Safety Assessment Sales Value Market Share by Country (2021-2026) Table 36. Global Pharmaceutical Safety Assessment Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Pharmaceutical Safety Assessment Sales Value Market Share by Country (2027-2032) Table 38. Eurofins Company Information Table 39. Eurofins Business Overview Table 40. Eurofins Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Eurofins Pharmaceutical Safety Assessment Product Portfolio Table 42. Eurofins Recent Development Table 43. LabCorp Company Information Table 44. LabCorp Business Overview Table 45. LabCorp Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. LabCorp Pharmaceutical Safety Assessment Product Portfolio Table 47. LabCorp Recent Development Table 48. Fujifilm Wako Company Information Table 49. Fujifilm Wako Business Overview Table 50. Fujifilm Wako Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Fujifilm Wako Pharmaceutical Safety Assessment Product Portfolio Table 52. Fujifilm Wako Recent Development Table 53. Charles River Company Information Table 54. Charles River Business Overview Table 55. Charles River Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Charles River Pharmaceutical Safety Assessment Product Portfolio Table 57. Charles River Recent Development Table 58. SGS Company Information Table 59. SGS Business Overview Table 60. SGS Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. SGS Pharmaceutical Safety Assessment Product Portfolio Table 62. SGS Recent Development Table 63. Intertek Group Company Information Table 64. Intertek Group Business Overview Table 65. Intertek Group Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Intertek Group Pharmaceutical Safety Assessment Product Portfolio Table 67. Intertek Group Recent Development Table 68. CTI Company Information Table 69. CTI Business Overview Table 70. CTI Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CTI Pharmaceutical Safety Assessment Product Portfolio Table 72. CTI Recent Development Table 73. Frontage Company Information Table 74. Frontage Business Overview Table 75. Frontage Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Frontage Pharmaceutical Safety Assessment Product Portfolio Table 77. Frontage Recent Development Table 78. Medicilon Company Information Table 79. Medicilon Business Overview Table 80. Medicilon Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Medicilon Pharmaceutical Safety Assessment Product Portfolio Table 82. Medicilon Recent Development Table 83. Wuxi Biologics Company Information Table 84. Wuxi Biologics Business Overview Table 85. Wuxi Biologics Pharmaceutical Safety Assessment Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Wuxi Biologics Pharmaceutical Safety Assessment Product Portfolio Table 87. Wuxi Biologics Recent Development Table 88. Pharmaron Company Information Table 89. Pharmaron Business Overview Table 90. Pharmaron Pharmaceutical Safety Assessment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Pharmaron Pharmaceutical Safety Assessment Product Portfolio Table 92. Pharmaron Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Pharmaceutical Safety Assessment Product Image Figure 2. Global Pharmaceutical Safety Assessment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmaceutical Safety Assessment Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharmaceutical Safety Assessment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Biological Drugs Image Figure 8. Chemical Drugs Image Figure 9. Global Pharmaceutical Safety Assessment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Pharmaceutical Safety Assessment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Pharmaceutical Safety Assessment Sales Value Share by Type (2021-2032) Figure 12. Clinical Image Figure 13. Non-clinical Image Figure 14. Global Pharmaceutical Safety Assessment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pharmaceutical Safety Assessment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pharmaceutical Safety Assessment Sales Value Share by Application (2021-2032) Figure 17. Global Pharmaceutical Safety Assessment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Pharmaceutical Safety Assessment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Pharmaceutical Safety Assessment Sales Value (2021-2032) & (US$ Million) Figure 20. North America Pharmaceutical Safety Assessment Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Pharmaceutical Safety Assessment Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Pharmaceutical Safety Assessment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Pharmaceutical Safety Assessment Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Pharmaceutical Safety Assessment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Pharmaceutical Safety Assessment Sales Value (2021-2032) & (US$ Million) Figure 26. South America Pharmaceutical Safety Assessment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Pharmaceutical Safety Assessment Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Pharmaceutical Safety Assessment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Biological Drugs
  • Chemical Drugs
Applications
  • Clinical
  • Non-clinical
Companies covered
  • Eurofins
  • LabCorp
  • Fujifilm Wako
  • Charles River
  • SGS
  • Intertek Group
  • CTI
  • Frontage
  • Medicilon
  • Wuxi Biologics
  • Pharmaron

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharmaceutical Safety Assessment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharmaceutical Safety Assessment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharmaceutical Safety Assessment Market Dynamics
  1. 2.1 Pharmaceutical Safety Assessment Industry Trends
  2. 2.2 Pharmaceutical Safety Assessment Industry Drivers
  3. 2.3 Pharmaceutical Safety Assessment Industry Opportunities and Challenges
  4. 2.4 Pharmaceutical Safety Assessment Industry Restraints
3 Pharmaceutical Safety Assessment Market by Company
  1. 3.1 Global Pharmaceutical Safety Assessment Company Revenue Ranking in 2025
  2. 3.2 Global Pharmaceutical Safety Assessment Revenue by Company (2021-2026)
  3. 3.3 Global Pharmaceutical Safety Assessment Company Ranking (2024-2026)
  4. 3.4 Global Pharmaceutical Safety Assessment Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharmaceutical Safety Assessment Company Product Type and Application
  6. 3.6 Global Pharmaceutical Safety Assessment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharmaceutical Safety Assessment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharmaceutical Safety Assessment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharmaceutical Safety Assessment Market by Type
  1. 4.1 Pharmaceutical Safety Assessment Type Introduction
  2. 4.1.1 Biological Drugs
  3. 4.1.2 Chemical Drugs
  4. 4.2 Global Pharmaceutical Safety Assessment Sales Value by Type
  5. 4.2.1 Global Pharmaceutical Safety Assessment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pharmaceutical Safety Assessment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Pharmaceutical Safety Assessment Sales Value Share by Type (2021-2032)
5 Pharmaceutical Safety Assessment Market by Application
  1. 5.1 Pharmaceutical Safety Assessment Application Introduction
  2. 5.1.1 Clinical
  3. 5.1.2 Non-clinical
  4. 5.2 Global Pharmaceutical Safety Assessment Sales Value by Application
  5. 5.2.1 Global Pharmaceutical Safety Assessment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pharmaceutical Safety Assessment Sales Value by Application (2021-2032)
  7. 5.2.3 Global Pharmaceutical Safety Assessment Sales Value Share by Application (2021-2032)
6 Pharmaceutical Safety Assessment Regional Value Analysis
  1. 6.1 Global Pharmaceutical Safety Assessment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmaceutical Safety Assessment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharmaceutical Safety Assessment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharmaceutical Safety Assessment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharmaceutical Safety Assessment Sales Value (2021-2032)
  7. 6.3.2 North America Pharmaceutical Safety Assessment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharmaceutical Safety Assessment Sales Value (2021-2032)
  10. 6.4.2 Europe Pharmaceutical Safety Assessment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharmaceutical Safety Assessment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharmaceutical Safety Assessment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharmaceutical Safety Assessment Sales Value (2021-2032)
  16. 6.6.2 South America Pharmaceutical Safety Assessment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharmaceutical Safety Assessment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharmaceutical Safety Assessment Sales Value Share by Country, 2025 VS 2032
7 Pharmaceutical Safety Assessment Country-level Value Analysis
  1. 7.1 Global Pharmaceutical Safety Assessment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmaceutical Safety Assessment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharmaceutical Safety Assessment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharmaceutical Safety Assessment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharmaceutical Safety Assessment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharmaceutical Safety Assessment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharmaceutical Safety Assessment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eurofins
  2. 8.1.1 Eurofins Company Information
  3. 8.1.2 Eurofins Business Overview
  4. 8.1.3 Eurofins Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eurofins Pharmaceutical Safety Assessment Product Portfolio
  6. 8.1.5 Eurofins Recent Developments
  7. 8.2 LabCorp
  8. 8.2.1 LabCorp Company Information
  9. 8.2.2 LabCorp Business Overview
  10. 8.2.3 LabCorp Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 LabCorp Pharmaceutical Safety Assessment Product Portfolio
  12. 8.2.5 LabCorp Recent Developments
  13. 8.3 Fujifilm Wako
  14. 8.3.1 Fujifilm Wako Company Information
  15. 8.3.2 Fujifilm Wako Business Overview
  16. 8.3.3 Fujifilm Wako Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fujifilm Wako Pharmaceutical Safety Assessment Product Portfolio
  18. 8.3.5 Fujifilm Wako Recent Developments
  19. 8.4 Charles River
  20. 8.4.1 Charles River Company Information
  21. 8.4.2 Charles River Business Overview
  22. 8.4.3 Charles River Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Charles River Pharmaceutical Safety Assessment Product Portfolio
  24. 8.4.5 Charles River Recent Developments
  25. 8.5 SGS
  26. 8.5.1 SGS Company Information
  27. 8.5.2 SGS Business Overview
  28. 8.5.3 SGS Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SGS Pharmaceutical Safety Assessment Product Portfolio
  30. 8.5.5 SGS Recent Developments
  31. 8.6 Intertek Group
  32. 8.6.1 Intertek Group Company Information
  33. 8.6.2 Intertek Group Business Overview
  34. 8.6.3 Intertek Group Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Intertek Group Pharmaceutical Safety Assessment Product Portfolio
  36. 8.6.5 Intertek Group Recent Developments
  37. 8.7 CTI
  38. 8.7.1 CTI Company Information
  39. 8.7.2 CTI Business Overview
  40. 8.7.3 CTI Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CTI Pharmaceutical Safety Assessment Product Portfolio
  42. 8.7.5 CTI Recent Developments
  43. 8.8 Frontage
  44. 8.8.1 Frontage Company Information
  45. 8.8.2 Frontage Business Overview
  46. 8.8.3 Frontage Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Frontage Pharmaceutical Safety Assessment Product Portfolio
  48. 8.8.5 Frontage Recent Developments
  49. 8.9 Medicilon
  50. 8.9.1 Medicilon Company Information
  51. 8.9.2 Medicilon Business Overview
  52. 8.9.3 Medicilon Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medicilon Pharmaceutical Safety Assessment Product Portfolio
  54. 8.9.5 Medicilon Recent Developments
  55. 8.10 Wuxi Biologics
  56. 8.10.1 Wuxi Biologics Company Information
  57. 8.10.2 Wuxi Biologics Business Overview
  58. 8.10.3 Wuxi Biologics Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Wuxi Biologics Pharmaceutical Safety Assessment Product Portfolio
  60. 8.10.5 Wuxi Biologics Recent Developments
  61. 8.11 Pharmaron
  62. 8.11.1 Pharmaron Company Information
  63. 8.11.2 Pharmaron Business Overview
  64. 8.11.3 Pharmaron Pharmaceutical Safety Assessment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pharmaron Pharmaceutical Safety Assessment Product Portfolio
  66. 8.11.5 Pharmaron Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst